Float Short %

14.11

Margin Of Safety %

Put/Call OI Ratio

0.1

EPS Next Q Diff

-0.02

EPS Last/This Y

0.46

EPS This/Next Y

-0.08

Price

1.48

Target Price

2.92

Analyst Recom

1.8

Performance Q

Upside

-268.0%

Beta

0.93

Ticker: LXRX

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	LXRX	1.705	0.05	0.15	28545
2026-01-26	LXRX	1.57	0.05	0.04	28703
2026-01-27	LXRX	1.71	0.05	0.00	28767
2026-01-28	LXRX	1.505	0.05	0.03	29341
2026-01-29	LXRX	1.435	0.05	0.01	29644
2026-01-30	LXRX	1.16	0.05	0.37	30542
2026-02-02	LXRX	1.245	0.09	0.06	35465
2026-02-03	LXRX	1.28	0.09	0.00	36584
2026-02-04	LXRX	1.285	0.09	0.56	36745
2026-02-05	LXRX	1.175	0.10	0.00	37223
2026-02-06	LXRX	1.23	0.10	0.05	36228
2026-02-09	LXRX	1.205	0.10	0.05	36342
2026-02-10	LXRX	1.305	0.10	0.05	36403
2026-02-11	LXRX	1.38	0.10	0.01	36440
2026-02-12	LXRX	1.315	0.10	0.00	36516
2026-02-13	LXRX	1.315	0.10	0.00	36862
2026-02-17	LXRX	1.315	0.10	0.00	37117
2026-02-18	LXRX	1.325	0.10	0.01	37507
2026-02-19	LXRX	1.52	0.10	0.08	38069
2026-02-20	LXRX	1.48	0.10	0.00	39320
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	LXRX	1.71	21.1	-45.4	-0.17
2026-01-26	LXRX	1.58	21.1	-40.4	-0.17
2026-01-27	LXRX	1.71	21.1	-59.8	-0.17
2026-01-28	LXRX	1.50	21.1	-35.0	-0.17
2026-01-29	LXRX	1.44	21.1	-44.4	-0.17
2026-01-30	LXRX	1.15	21.1	-25.6	-0.17
2026-02-02	LXRX	1.25	21.1	-59.3	-0.17
2026-02-03	LXRX	1.28	21.1	-52.2	-0.17
2026-02-04	LXRX	1.28	21.1	-50.0	-0.17
2026-02-05	LXRX	1.17	21.1	-39.6	-0.17
2026-02-06	LXRX	1.23	21.1	-53.7	-0.17
2026-02-09	LXRX	1.20	21.1	-46.6	-0.17
2026-02-10	LXRX	1.30	21.1	-59.8	-0.17
2026-02-11	LXRX	1.38	21.1	-55.6	-0.17
2026-02-12	LXRX	1.31	21.1	-43.5	-0.17
2026-02-13	LXRX	1.31	21.1	-48.2	-0.17
2026-02-17	LXRX	1.32	21.1	-48.7	-0.17
2026-02-18	LXRX	1.33	21.1	-50.5	-0.17
2026-02-19	LXRX	1.52	21.1	-	-0.17
2026-02-20	LXRX	1.48	21.1	-	-0.17
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	LXRX	0.00	-0.30	12.86
2026-01-26	LXRX	0.00	-0.32	12.86
2026-01-27	LXRX	0.00	-0.32	12.86
2026-01-28	LXRX	0.00	-0.32	13.67
2026-01-29	LXRX	0.00	-0.32	13.67
2026-01-30	LXRX	0.00	-0.32	13.67
2026-02-02	LXRX	0.00	-0.30	13.67
2026-02-03	LXRX	0.00	-0.30	13.67
2026-02-04	LXRX	0.79	-0.30	13.67
2026-02-05	LXRX	0.79	-0.30	12.56
2026-02-06	LXRX	0.79	-0.30	12.56
2026-02-09	LXRX	0.79	0.24	14.30
2026-02-10	LXRX	0.71	0.24	14.30
2026-02-11	LXRX	0.71	0.24	13.97
2026-02-12	LXRX	0.71	0.24	13.97
2026-02-13	LXRX	0.71	0.24	13.97
2026-02-17	LXRX	0.71	1.23	14.11
2026-02-18	LXRX	0.82	1.23	14.11
2026-02-19	LXRX	0.82	1.23	14.11
2026-02-20	LXRX	0.82	1.23	14.11
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.04

Avg. EPS Est. Current Quarter

-0.07

Avg. EPS Est. Next Quarter

-0.07

Insider Transactions

0.82

Institutional Transactions

1.23

Beta

0.93

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

81.8

Max Drawdown 5-Year %

-96.2

Target Price

2.92

P/E

Forward P/E

PEG

P/S

8.2

P/B

4.45

P/Free Cash Flow

EPS

-0.19

Average EPS Est. Cur. Y

-0.17

EPS Next Y. (Est.)

-0.25

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-96.77

Relative Volume

0.94

Return on Equity vs Sector %

-86.1

Return on Equity vs Industry %

-68.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Lexicon Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 103

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

stock quote shares LXRX – Lexicon Pharmaceuticals, Inc. Stock Price stock today

news today LXRX – Lexicon Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch LXRX – Lexicon Pharmaceuticals, Inc. yahoo finance google finance

stock history LXRX – Lexicon Pharmaceuticals, Inc. invest stock market

stock prices LXRX premarket after hours

ticker LXRX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: LXRX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y